Thiago Carvalho · @cyrilpedia
1907 followers · 11711 posts · Server qoto.org

"Although marketed CAR-T therapies have shown transformative efficacy for certain blood cancers, widespread adoption, as well as applicability to solid tumours and autoimmune indications, have been limited by safety, efficacy and operational hurdles. These hurdles include high rates of adverse events such as cytokine release syndrome (CRS), inability to overcome the immunosuppressive microenvironment typically found in solid tumours, and antigen escape and cell exhaustion that reduce durability."

nature.com/articles/d41573-023

#immunotherapy #immunology #CARTCells

Last updated 2 years ago

Thiago Carvalho · @cyrilpedia
1874 followers · 10549 posts · Server qoto.org

"Another key parameter in CAR T cell infusion products is the ratio of CD4:CD8 T cell subsets. Yet, it is unclear whether CD4+ and CD8+ CAR T cells have the same propensity to induce CRS. This is particularly relevant since CD4:CD8 ratios can vary extensively in distinct infusion products."

cell.com/cell-reports-medicine

#immunology #immunotherapy #CARTCells

Last updated 2 years ago

Thiago Carvalho · @cyrilpedia
1813 followers · 9664 posts · Server qoto.org

BCMA targeting CARTs in

"At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group."

nejm.org/doi/full/10.1056/NEJM

#multiplemyeloma #immunology #immunotherapy #CARTCells

Last updated 2 years ago

Thiago Carvalho · @cyrilpedia
1620 followers · 6365 posts · Server qoto.org

'Most of these studies have focused on immune checkpoint blockade, although effects of the microbiota on clinical outcomes have also been observed in allogeneic hematopoietic stem cell transplant (which can be considered a very broad form of ).'

nature.com/articles/s41591-023

#immunology #CARTCells #immunotherapy

Last updated 2 years ago

Thiago Carvalho · @cyrilpedia
1619 followers · 6247 posts · Server qoto.org

Antigen independent metabolic effects of CAR constructs:

"Here we show that CARs differing only in the scFv reprogram T-cell metabolism differently. Even in the absence of antigens, some CARs increase proliferation and nutrient uptake in T cells."

biorxiv.org/content/10.1101/20

#immunology #preprint #immunotherapy #CARTCells

Last updated 2 years ago

Thiago Carvalho · @cyrilpedia
1593 followers · 5697 posts · Server qoto.org

From Carl June et al

"A fundamental limitation of T cell therapies in solid tumors is loss of inflammatory effector functions, such as cytokine production and proliferation. Here, we target a regulatory axis of T cell inflammatory responses, Regnase-1 and Roquin-1, to enhance antitumor responses in human T cells engineered with two clinical-stage immune receptors."

pnas.org/doi/10.1073/pnas.2218

#CARTCells #immunotherapy #immunology

Last updated 2 years ago

Thiago Carvalho · @cyrilpedia
1585 followers · 5578 posts · Server qoto.org

Anti-BCMA CART cells in relapsed and refractory multiple myeloma.

"At a median follow-up of 18.6 months, the median progression-free survival was 13.3 months in the ide-cel group, as compared with 4.4 months in the standard-regimen group (hazard ratio for disease progression or death, 0.49; 95% confidence interval, 0.38 to 0.65; P<0.001). A response occurred in 71% of the patients in the ide-cel group and in 42% of those in the standard-regimen group (P<0.001); a complete response occurred in 39% and 5%, respectively."

nejm.org/doi/full/10.1056/NEJM

#immunotherapy #CARTCells #multiplemyeloma #immunology

Last updated 2 years ago

Yan Leyfman, MD · @yleyfman
125 followers · 193 posts · Server med-mastodon.com
Thiago Carvalho · @cyrilpedia
1500 followers · 4332 posts · Server qoto.org

'Even so, the challenge of making such a ‘living drug’ from a person’s cells extends beyond complicated designs. Safety and manufacturing problems remain to be addressed for many of the newest candidates. “There’s an explosion of very fancy things, and I think that’s great,” says immunologist Michel Sadelain at the Memorial Sloan Kettering Cancer Center in New York City. “But the complexity cannot always be brought as described into a clinical setting.”

nature.com/articles/d41586-023

#CARTCells #immunotherapy

Last updated 3 years ago

Thiago Carvalho · @cyrilpedia
1494 followers · 4203 posts · Server qoto.org

'Crystal Mackall remembers her scepticism the first time she heard a talk about a way to engineer T cells to recognize and kill cancer. Sitting in the audience at a 1996 meeting in Germany, the paediatric oncologist turned to the person next to her and said: “No way. That’s too crazy.”

nature.com/articles/d41586-023

#immunotherapy #CARTCells #immunology

Last updated 3 years ago

Thiago Carvalho · @cyrilpedia
1479 followers · 4051 posts · Server qoto.org

Off-the-shelf CARTs

"Nevertheless, generation of autologous CAR T cell products is extremely time consuming and costly, prompting researchers to explore alternative strategies to overcome these limitations. In this issue of Nature Medicine, Mailankody et al.4 report results of part A of the phase 1 UNIVERSAL clinical trial, which evaluated ALLO-715, an allogeneic off-the-shelf anti-BCMA CAR T cell product."

nature.com/articles/s41591-022

#naturemedicine #CARTCells #immunology #immunotherapy #multiplemyeloma #hematology

Last updated 3 years ago

Early results look promising.

Would be fantastic if this moves the needle for these patients!

RT @CD_AACR@twitter.com

In the January issue of Cancer Discovery—
Intraventricular B7-H3 for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety, by @VitanzaNick@twitter.com, Michael Jensen, Julie Park et al.
bit.ly/3R2iQWl
@seattlechildren@twitter.com @SCTherapeutics@twitter.com

🐦🔗: twitter.com/CD_AACR/status/161

#CARTCells #DIPG

Last updated 3 years ago

Yan Leyfman, MD · @yleyfman
124 followers · 155 posts · Server med-mastodon.com
Thiago Carvalho · @cyrilpedia
1375 followers · 3263 posts · Server qoto.org

A review of cardiotoxicity in CART therapy in the European Heart Journal. Not surprisingly, a lot of it is linked to cytokine release syndrome. Includes also a brief look at the interesting possibility of using CART to treat heart disease.

academic.oup.com/eurheartj/art

#immunotherapy #immunology #CARTCells

Last updated 3 years ago

Yan Leyfman, MD · @yleyfman
118 followers · 126 posts · Server med-mastodon.com
Yan Leyfman, MD · @yleyfman
117 followers · 117 posts · Server med-mastodon.com
Yan Leyfman, MD · @yleyfman
115 followers · 108 posts · Server med-mastodon.com
Yan Leyfman, MD · @yleyfman
113 followers · 103 posts · Server med-mastodon.com
Yan Leyfman, MD · @yleyfman
108 followers · 97 posts · Server med-mastodon.com
Simon Castillo · @simoncastillo
34 followers · 12 posts · Server ecoevo.social

Outwitting immunosuppressive TMEs 👏💡

Allen et al. re-engineered CAR-T cells w a 2nd receptor that recognises neoantigen and causes a local cytokine-mediated boost of T cell proliferation overcoming immunosuppressive conditions.

science.org/doi/10.1126/scienc

#cancer #Immunotherapy #CARTCells

Last updated 3 years ago